# Dimas Timmers

> Dimas Timmers is a startup investor at Raras Health. See 0 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Raras Health](https://shizune.co/investors/profile/raras-health)
- Last updated: Aug 2026

Dimas Timmers is a startup investor at Raras Health.

## About Raras Health

VC Fund · São Paulo, Brazil

Raras Health is a Brazilian health technology company building AI infrastructure for rare disease diagnosis. An estimated 300 million people worldwide live with one of more than 7,000 known rare diseases, and the average patient endures a diagnostic odyssey of five to seven years across multiple specialists before receiving an accurate diagnosis.Raras was founded to compress that timeline through a combination of advanced AI, biomedical knowledge engineering, and clinical partnerships.The company's flagship product, My Scientist, is a multi-agent on-premise AI platform that supports clinicians in evaluating complex undiagnosed cases. It combines specialized agents for phenotype extraction, genomics analysis, knowledge-graph reasoning, literature review, differential diagnosis, and treatment guidance. On RareBench, the leading public benchmark for rare disease diagnostic AI, My Scientist achieves Recall@1 of 66.7% and Recall@5 of 86.7%, placing it among the strongest rare disease diagnostic systems published to date. The platform is deployed on-premise to meet hospital data governance requirements and is powered by open-source foundation models served through vLLM, alongside Araras-HPO, the company's proprietary Portuguese-language biomedical language model.Raras Enciclopédia serves as the underlying knowledge and ontology layer, integrating data on more than 10,468 rare diseases across a graph of over 927,000 nodes and 5.4 million edges. The encyclopedia consolidates international ontologies (HPO, Orphanet, OMIM, MONDO) with curated clinical knowledge into a unified resource that powers both clinical decision support and patient-facing applications. Raras is co-founded by Dimas Timmers (CEO), a deep-tech AI entrepreneur with prior experience at Antler and Meta, and previously founder of Nindoo, an AI lab focused on federated learning in healthcare; Dr. Alexandre Kawassaki (CMO), a rare disease specialist at Hospital das Clínicas da Universidade de São Paulo and LinkedIn Top Voice in Healthcare; and Dr. João Bosco Oliveira Filho (CSO), holder of dual PhDs from USP and the University of Amsterdam, post-doctorate at the U.S. National Institutes of Health, founder of NeoGenomica, and former principal investigator of the Rare Genomes Project at Hospital Israelita Albert Einstein.Raras maintains institutional partnerships with Hospital das Clínicas da Universidade de São Paulo, Instituto Jô Clemente. The company is headquartered in Brazil, with European expansion underway in Lisbon, Portugal.Menos sorte. Mais respostas. (Less luck. More answers.)

2 contacts available at Raras Health.

| Name | Title | Profile |
| --- | --- | --- |
| Alexandre Kawassaki | CMO | https://shizune.co/investors/profile/alexandre-kawassaki |
| Dimas Timmers | CEO | https://shizune.co/investors/profile/dimas-timmers |

## FAQ

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co